Selected research
Industry Research
Ovulation Induction Industry Research Report 2026
Market perspective
The global Ovulation Induction market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Ovulation Induction market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Ovulation Induction market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Ovulation Induction market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Ovulation Induction include Takeda, Sanofi, Merck & Co. Inc, AbbVie, AstraZeneca, Unichem Laboratories, Teva Pharmaceuticals USA, Inc, TerSera Therapeutics and Techwell, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Ovulation Induction market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Ovulation Induction.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ovulation Induction Market by Company
Takeda
Sanofi
Merck & Co. Inc
AbbVie
AstraZeneca
Unichem Laboratories
Teva Pharmaceuticals USA, Inc
TerSera Therapeutics
Techwell
Sun Pharmaceutical
Pharmascience Inc
Par pharmaceutical inc
Pacific Pharmaceuticals
LIVZON
Ipsen
IBSA
IBM Micromedex
Gedeon Richter
Fresenius Kabi
Ferring
Endo
EMD Serono Inc
Emcure Pharmaceuticals Ltd.
Cosette Pharmaceuticals, Inc
Bristol Myers Squibb
Ovulation Induction Segment by Type
Follicle Stimulating Hormone
Clomiphene Citrate
Human Menopausal Gonadotropin
Human Chorionic Gonadotropin
Others
Ovulation Induction Segment by Application
Clinic
Hospital
Medical Institution
Ovulation Induction Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ovulation Induction market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ovulation Induction and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ovulation Induction.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Ovulation Induction companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Follicle Stimulating Hormone
- Clomiphene Citrate
- Human Menopausal Gonadotropin
- Human Chorionic Gonadotropin
- Others
Applications
- Clinic
- Hospital
- Medical Institution
Companies covered
- Takeda
- Sanofi
- Merck & Co. Inc
- AbbVie
- AstraZeneca
- Unichem Laboratories
- Teva Pharmaceuticals USA, Inc
- TerSera Therapeutics
- Techwell
- Sun Pharmaceutical
- Pharmascience Inc
- Par pharmaceutical inc
- Pacific Pharmaceuticals
- LIVZON
- Ipsen
- IBSA
- IBM Micromedex
- Gedeon Richter
- Fresenius Kabi
- Ferring
- Endo
- EMD Serono Inc
- Emcure Pharmaceuticals Ltd.
- Cosette Pharmaceuticals, Inc
- Bristol Myers Squibb
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Ovulation Induction by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Follicle Stimulating Hormone
- 2.2.3 Clomiphene Citrate
- 2.2.4 Human Menopausal Gonadotropin
- 2.2.5 Human Chorionic Gonadotropin
- 2.2.6 Others
- 2.3 Ovulation Induction by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Medical Institution
- 2.4 Assumptions and Limitations
3 Ovulation Induction Breakdown Data by Type
- 3.1 Global Ovulation Induction Historic Market Size by Type (2021-2026)
- 3.2 Global Ovulation Induction Forecasted Market Size by Type (2027-2032)
4 Ovulation Induction Breakdown Data by Application
- 4.1 Global Ovulation Induction Historic Market Size by Application (2021-2026)
- 4.2 Global Ovulation Induction Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Ovulation Induction Market Perspective (2021-2032)
- 5.2 Global Ovulation Induction Growth Trends by Region
- 5.2.1 Global Ovulation Induction Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Ovulation Induction Historic Market Size by Region (2021-2026)
- 5.2.3 Ovulation Induction Forecasted Market Size by Region (2027-2032)
- 5.3 Ovulation Induction Market Dynamics
- 5.3.1 Ovulation Induction Industry Trends
- 5.3.2 Ovulation Induction Market Drivers
- 5.3.3 Ovulation Induction Market Challenges
- 5.3.4 Ovulation Induction Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Ovulation Induction Players by Revenue
- 6.1.1 Global Top Ovulation Induction Players by Revenue (2021-2026)
- 6.1.2 Global Ovulation Induction Revenue Market Share by Players (2021-2026)
- 6.2 Global Ovulation Induction Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Ovulation Induction Head Office and Area Served
- 6.4 Global Ovulation Induction Players, Product Type & Application
- 6.5 Global Ovulation Induction Manufacturers Established Date
- 6.6 Global Ovulation Induction Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Ovulation Induction Market Size (2021-2032)
- 7.2 North America Ovulation Induction Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Ovulation Induction Market Size by Country (2021-2026)
- 7.4 North America Ovulation Induction Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Ovulation Induction Market Size (2021-2032)
- 8.2 Europe Ovulation Induction Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Ovulation Induction Market Size by Country (2021-2026)
- 8.4 Europe Ovulation Induction Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Ovulation Induction Market Size (2021-2032)
- 9.2 Asia-Pacific Ovulation Induction Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Ovulation Induction Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Ovulation Induction Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Ovulation Induction Market Size (2021-2032)
- 10.2 South America Ovulation Induction Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Ovulation Induction Market Size by Country (2021-2026)
- 10.4 South America Ovulation Induction Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Ovulation Induction Market Size (2021-2032)
- 11.2 Middle East & Africa Ovulation Induction Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Ovulation Induction Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Ovulation Induction Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Ovulation Induction Business (2021-2026)
- 12.1.4 Takeda Ovulation Induction Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Ovulation Induction Business (2021-2026)
- 12.2.4 Sanofi Ovulation Induction Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Merck & Co. Inc
- 12.3.1 Merck & Co. Inc Company Information
- 12.3.2 Merck & Co. Inc Business Overview
- 12.3.3 Merck & Co. Inc Revenue in Ovulation Induction Business (2021-2026)
- 12.3.4 Merck & Co. Inc Ovulation Induction Product Portfolio
- 12.3.5 Merck & Co. Inc Recent Developments
- 12.4 AbbVie
- 12.4.1 AbbVie Company Information
- 12.4.2 AbbVie Business Overview
- 12.4.3 AbbVie Revenue in Ovulation Induction Business (2021-2026)
- 12.4.4 AbbVie Ovulation Induction Product Portfolio
- 12.4.5 AbbVie Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Ovulation Induction Business (2021-2026)
- 12.5.4 AstraZeneca Ovulation Induction Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Unichem Laboratories
- 12.6.1 Unichem Laboratories Company Information
- 12.6.2 Unichem Laboratories Business Overview
- 12.6.3 Unichem Laboratories Revenue in Ovulation Induction Business (2021-2026)
- 12.6.4 Unichem Laboratories Ovulation Induction Product Portfolio
- 12.6.5 Unichem Laboratories Recent Developments
- 12.7 Teva Pharmaceuticals USA, Inc
- 12.7.1 Teva Pharmaceuticals USA, Inc Company Information
- 12.7.2 Teva Pharmaceuticals USA, Inc Business Overview
- 12.7.3 Teva Pharmaceuticals USA, Inc Revenue in Ovulation Induction Business (2021-2026)
- 12.7.4 Teva Pharmaceuticals USA, Inc Ovulation Induction Product Portfolio
- 12.7.5 Teva Pharmaceuticals USA, Inc Recent Developments
- 12.8 TerSera Therapeutics
- 12.8.1 TerSera Therapeutics Company Information
- 12.8.2 TerSera Therapeutics Business Overview
- 12.8.3 TerSera Therapeutics Revenue in Ovulation Induction Business (2021-2026)
- 12.8.4 TerSera Therapeutics Ovulation Induction Product Portfolio
- 12.8.5 TerSera Therapeutics Recent Developments
- 12.9 Techwell
- 12.9.1 Techwell Company Information
- 12.9.2 Techwell Business Overview
- 12.9.3 Techwell Revenue in Ovulation Induction Business (2021-2026)
- 12.9.4 Techwell Ovulation Induction Product Portfolio
- 12.9.5 Techwell Recent Developments
- 12.10 Sun Pharmaceutical
- 12.10.1 Sun Pharmaceutical Company Information
- 12.10.2 Sun Pharmaceutical Business Overview
- 12.10.3 Sun Pharmaceutical Revenue in Ovulation Induction Business (2021-2026)
- 12.10.4 Sun Pharmaceutical Ovulation Induction Product Portfolio
- 12.10.5 Sun Pharmaceutical Recent Developments
- 12.11 Pharmascience Inc
- 12.11.1 Pharmascience Inc Company Information
- 12.11.2 Pharmascience Inc Business Overview
- 12.11.3 Pharmascience Inc Revenue in Ovulation Induction Business (2021-2026)
- 12.11.4 Pharmascience Inc Ovulation Induction Product Portfolio
- 12.11.5 Pharmascience Inc Recent Developments
- 12.12 Par pharmaceutical inc
- 12.12.1 Par pharmaceutical inc Company Information
- 12.12.2 Par pharmaceutical inc Business Overview
- 12.12.3 Par pharmaceutical inc Revenue in Ovulation Induction Business (2021-2026)
- 12.12.4 Par pharmaceutical inc Ovulation Induction Product Portfolio
- 12.12.5 Par pharmaceutical inc Recent Developments
- 12.13 Pacific Pharmaceuticals
- 12.13.1 Pacific Pharmaceuticals Company Information
- 12.13.2 Pacific Pharmaceuticals Business Overview
- 12.13.3 Pacific Pharmaceuticals Revenue in Ovulation Induction Business (2021-2026)
- 12.13.4 Pacific Pharmaceuticals Ovulation Induction Product Portfolio
- 12.13.5 Pacific Pharmaceuticals Recent Developments
- 12.14 LIVZON
- 12.14.1 LIVZON Company Information
- 12.14.2 LIVZON Business Overview
- 12.14.3 LIVZON Revenue in Ovulation Induction Business (2021-2026)
- 12.14.4 LIVZON Ovulation Induction Product Portfolio
- 12.14.5 LIVZON Recent Developments
- 12.15 Ipsen
- 12.15.1 Ipsen Company Information
- 12.15.2 Ipsen Business Overview
- 12.15.3 Ipsen Revenue in Ovulation Induction Business (2021-2026)
- 12.15.4 Ipsen Ovulation Induction Product Portfolio
- 12.15.5 Ipsen Recent Developments
- 12.16 IBSA
- 12.16.1 IBSA Company Information
- 12.16.2 IBSA Business Overview
- 12.16.3 IBSA Revenue in Ovulation Induction Business (2021-2026)
- 12.16.4 IBSA Ovulation Induction Product Portfolio
- 12.16.5 IBSA Recent Developments
- 12.17 IBM Micromedex
- 12.17.1 IBM Micromedex Company Information
- 12.17.2 IBM Micromedex Business Overview
- 12.17.3 IBM Micromedex Revenue in Ovulation Induction Business (2021-2026)
- 12.17.4 IBM Micromedex Ovulation Induction Product Portfolio
- 12.17.5 IBM Micromedex Recent Developments
- 12.18 Gedeon Richter
- 12.18.1 Gedeon Richter Company Information
- 12.18.2 Gedeon Richter Business Overview
- 12.18.3 Gedeon Richter Revenue in Ovulation Induction Business (2021-2026)
- 12.18.4 Gedeon Richter Ovulation Induction Product Portfolio
- 12.18.5 Gedeon Richter Recent Developments
- 12.19 Fresenius Kabi
- 12.19.1 Fresenius Kabi Company Information
- 12.19.2 Fresenius Kabi Business Overview
- 12.19.3 Fresenius Kabi Revenue in Ovulation Induction Business (2021-2026)
- 12.19.4 Fresenius Kabi Ovulation Induction Product Portfolio
- 12.19.5 Fresenius Kabi Recent Developments
- 12.20 Ferring
- 12.20.1 Ferring Company Information
- 12.20.2 Ferring Business Overview
- 12.20.3 Ferring Revenue in Ovulation Induction Business (2021-2026)
- 12.20.4 Ferring Ovulation Induction Product Portfolio
- 12.20.5 Ferring Recent Developments
- 12.21 Endo
- 12.21.1 Endo Company Information
- 12.21.2 Endo Business Overview
- 12.21.3 Endo Revenue in Ovulation Induction Business (2021-2026)
- 12.21.4 Endo Ovulation Induction Product Portfolio
- 12.21.5 Endo Recent Developments
- 12.22 EMD Serono Inc
- 12.22.1 EMD Serono Inc Company Information
- 12.22.2 EMD Serono Inc Business Overview
- 12.22.3 EMD Serono Inc Revenue in Ovulation Induction Business (2021-2026)
- 12.22.4 EMD Serono Inc Ovulation Induction Product Portfolio
- 12.22.5 EMD Serono Inc Recent Developments
- 12.23 Emcure Pharmaceuticals Ltd.
- 12.23.1 Emcure Pharmaceuticals Ltd. Company Information
- 12.23.2 Emcure Pharmaceuticals Ltd. Business Overview
- 12.23.3 Emcure Pharmaceuticals Ltd. Revenue in Ovulation Induction Business (2021-2026)
- 12.23.4 Emcure Pharmaceuticals Ltd. Ovulation Induction Product Portfolio
- 12.23.5 Emcure Pharmaceuticals Ltd. Recent Developments
- 12.24 Cosette Pharmaceuticals, Inc
- 12.24.1 Cosette Pharmaceuticals, Inc Company Information
- 12.24.2 Cosette Pharmaceuticals, Inc Business Overview
- 12.24.3 Cosette Pharmaceuticals, Inc Revenue in Ovulation Induction Business (2021-2026)
- 12.24.4 Cosette Pharmaceuticals, Inc Ovulation Induction Product Portfolio
- 12.24.5 Cosette Pharmaceuticals, Inc Recent Developments
- 12.25 Bristol Myers Squibb
- 12.25.1 Bristol Myers Squibb Company Information
- 12.25.2 Bristol Myers Squibb Business Overview
- 12.25.3 Bristol Myers Squibb Revenue in Ovulation Induction Business (2021-2026)
- 12.25.4 Bristol Myers Squibb Ovulation Induction Product Portfolio
- 12.25.5 Bristol Myers Squibb Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst